Searched for
NEXAVAR DRUG
Natco Pharma's partner MylanInc gets USFDA nod for cancer drugThe company's marketing partner Mylan Inc has received a tentative approval from the United States Food and Drug Administration (USFDA).- Natco Pharma's US partner Mylan files application with USFDANatco Pharma's marketing partner Mylan Inc has filed an application with the US health regulator for generic Sorafenib tablets used mainly ...
- IPAB allows Natco Pharma to sell Nexavar; stock gains'Company will continue to market and sell the drug post verdict. It sold Rs 14 crore worth of Nexavar drug in the past 9 months.'
- Bayer says it will defend its intellectual property rights on cancer drugBayer today said it will continue to defend its IP rights while expressing disappointment at the IPAB decision to reject the firm's plea to...
- Patent drug prices to be set in negotiations with pharma companiesA panel set up to look into the pricing mechanism for patented drugs has said that prices have to be decided after deliberations with manuf...
- Pharma Department proposes negotiating patent drug rates with firmsThe department is the convener of an inter-ministerial group comprising DIPP and the Health Ministry to modulate a pricing mechanism for pa...
- Intellectual Property Appellate Board postpones Bayer's compulsory licence appealIPAB has postponed German company Bayer AG's appeal against the grant of a compulsory licence of its patented drug Nexavar to Natco Pharma ...
- US accuses India of WTO rules violation over Nexavar: ReportThe government had defended the move, with Commerce and Industry Minister Anand Sharma stating that India did not violate any WTO norms.
- Cipla breached patent rights by slashing cancer drug price: Bayer PharmaBayer has not given its consent to Cipla to launch its generic Sorafenib & co's decision to cut price "is clear patent infringement," Bayer...
- No applications pending from pharmaceutical companies seeking compulsory licenses: GovernmentThe government has clarified that no applications are pending from pharmaceutical companies seeking compulsory licences for producing low-c...
- Patented drugs: No application pending for compulsory license, says governmentAmid concerns that more domestic pharma companies could seek compulsory licenses to replicate patented drugs, the government said no such a...
- Bayer challenges Nexavar generic licence orderBayer has filed an appeal against a patents order, which allowed domestic drug maker Natco Pharma to sell a generic version of the German f...
- Natco Pharma bags licence to sell Nexavar drug; stock upShares of Natco Pharma extended gains for the second straight day on Tuesday after the company reported that it had received a license for ...
- Bayer drags Cipla to court over patentGerman drugmaker Bayer has filed a patent infringement case against Cipla, the largest domestic drug seller, to stop the Mumbai-based compa...
- SC rejects Bayer’s plea to stay Cipla’s cancer cloneThe Supreme Court turned down a request by German drugmaker Bayer AG to stop Mumbai-based Cipla from launching the low-cost version of Baye...
- No interim stay on Cipla’s Nexavar cloneThe Supreme Court turned down a request by German drugmaker Bayer AG to stop Mumbai-based Cipla from launching the low-cost version of Baye...
- Bayer’s bid to stay Cipla cancer drug foiled, next hearing on Oct 6Germany's largest drug maker Bayer failed to get a court stay on Cipla from seeking permission to launch the European company’s copycat of ...
- Cipla's clone of Bayer cancer drug gets nodThis case was keenly watched by both pharma industry and health activists because it had much wider ramifications.
- Major win for Indian pharma cos as HC dismisses Bayer petitionThe Delhi High Court (HC) on Tuesday dismissed German drug major Bayer Healthcare’s attempt to stop Drug Controller General of India (DCGI)...
- Cipla opposes patent for GSK’s cancer drugCipla has filed a grant opposition in the Kolkata patent office against GSK's newly-launched breast cancer drug on grounds of obviousness a...
Load More- Bayer says it will defend its intellectual property rights on cancer drug
